1DQ8 | C:464-536; A:462-536; B:462-536; D:462-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG AND COA |
1DQ9 | A:462-536; B:462-536; C:462-536; D:462-536 | COMPLEX OF CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG-COA |
1DQA | C:468-536; B:462-536; D:477-536; A:462-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH HMG, COA, AND NADP+ |
1HW8 | B:462-536; A:462-536; C:488-536; D:488-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH COMPACTIN (ALSO KNOWN AS MEVASTATIN) |
1HW9 | B:463-536; A:462-536; C:463-536; D:464-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH SIMVASTATIN |
1HWI | B:462-536; A:462-536; D:487-536; C:489-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH FLUVASTATIN |
1HWJ | B:463-536; D:462-536; A:462-536; C:462-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH CERIVASTATIN |
1HWK | B:463-536; A:462-536; C:462-536; D:463-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ATORVASTATIN |
1HWL | B:463-536; C:463-536; A:462-536; D:479-536 | COMPLEX OF THE CATALYTIC PORTION OF HUMAN HMG-COA REDUCTASE WITH ROSUVASTATIN (FORMALLY KNOWN AS ZD4522) |
2Q1L | C:462-536; A:459-536; D:462-536; B:459-536 | DESIGN AND SYNTHESIS OF PYRROLE-BASED, HEPATOSELECTIVE HMG-COA REDUCTASE INHIBITORS |
2Q6B | A:462-536; B:462-536; C:462-536; D:462-536 | DESIGN AND SYNTHESIS OF NOVEL, CONFORMATIONALLY RESTRICTED HMG-COA REDUCTASE INHIBITORS |
2Q6C | A:462-536; B:462-536; C:462-536; D:462-536 | DESIGN AND SYNTHESIS OF NOVEL, CONFORMATIONALLY RESTRICTED HMG-COA REDUCTASE INHIBITORS |
2R4F | D:458-536; A:462-536; B:462-536; C:462-536 | SUBSTITUTED PYRAZOLES AS HEPATSELECTIVE HMG-COA REDUCTASE INHIBITORS |
3BGL | A:462-536; B:462-536; C:462-536; D:459-536 | HEPATOSELECTIVITY OF STATINS: DESIGN AND SYNTHESIS OF 4-SULFAMOYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS |
3CCT | A:462-536; B:462-536; C:462-536; D:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CCW | A:462-536; B:462-536; C:462-536; D:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CCZ | D:458-536; A:462-536; B:462-536; C:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CD0 | D:458-536; A:462-536; B:462-536; C:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CD5 | A:462-536; B:462-536; C:462-536; D:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CD7 | C:462-536; A:459-536; D:462-536; B:459-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CDA | D:462-536; A:462-536; B:462-536; C:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |
3CDB | D:458-536; A:462-536; B:462-536; C:462-536 | THERMODYNAMIC AND STRUCTURE GUIDED DESIGN OF STATIN HMG-COA REDUCTASE INHIBITORS |